TransMedics Group (NASDAQ:TMDX) Posts Earnings Results, Misses Estimates By $0.03 EPS

TransMedics Group (NASDAQ:TMDX) posted its earnings results on Thursday. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.03), Zacks reports. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group updated its FY 2025 guidance to EPS.

TransMedics Group Trading Down 2.2 %

NASDAQ:TMDX traded down $1.64 on Thursday, hitting $72.12. 1,995,261 shares of the stock were exchanged, compared to its average volume of 2,142,666. The company’s 50-day moving average price is $67.29 and its 200 day moving average price is $102.44. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 76.72 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on TMDX. Canaccord Genuity Group decreased their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Finally, Piper Sandler reduced their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.